• Sign up to our Free Newsletter
  • Contact Us
  • Editorial Submission
Microbiome Times Magazine

Drug Database Powered by:

  • Human Health
  • Finance
  • Drug Database
    • Login
    • About
  • Issue Archive
  • Advertise
  • Recruitment Marketing

Month: April 2018

Finance

Belgian Microbiome Start-up A-Mansia Announces €13m First Close of Series A Financing

April 28, 2018 Microbiome Times

A-Mansia Biotech S.A. (A-Mansia), the microbiome company focused on developing products based on the unique properties of the Akkermansia muciniphila (A. muciniphila) bacterium, today announces a €13 million first close of its Series A financing, […]

Pharma & Human Health

Dutch Biotech Micreos ‘Alternative to Antibiotics’ Wins Ideas From Europe Finals

April 26, 2018 Microbiome Times

In the presence of Mrs. Elsbieta Bienkowska, European Commissioner Internal Market, Industry, Entrepeneurship and SMEs, and Mrs. Mona Keijzer, State Secretary Economic Affairs & Climate Policy, 12 finalists pitched their inspiring innovations to tackle global […]

Pharma & Human Health

The Global Prebiotic Association Welcomes Founding, Board and Associate Members

April 26, 2018 Microbiome Times

The Global Prebiotic Association (GPA), the association formed to steward growth of the category, today announced that Prenexus Health, Hayashibara (Nagase), Nutrasource Diagnostics and KGK Science have joined the organization. GPA has also added dietitian […]

Pharma & Human Health

New initiative in the fight against antibiotic resistance

April 26, 2018 Microbiome Times

The fight against the increasing and serious antibiotic resistance, that kills more and more people, is carried on many fronts. Organizations such as Strama and ReAct, as well as the Public Health Authority, work on […]

Finance

BioGaia AB – Interim management statement 1 January – 31 March 2018

April 25, 2018 Microbiome Times

Comments from the Managing Director: “Sales for the first quarter of 2018 amounted to SEK 157 million, which was an increase of 13% (excluding foreign exchange effects) compared to the corresponding period last year. Revenue […]

Pharma & Human Health

Drinking Affects Mouth Bacteria Linked to Diseases

April 24, 2018 Microbiome Times

When compared with nondrinkers, men and women who had one or more alcoholic drinks per day had an overabundance of oral bacteria linked to gum disease, some cancers, and heart disease. By contrast, drinkers had […]

Pharma & Human Health

Synthetic Biologics Provides Update on Development of SYN-004 (ribaxamase), for the Prevention of C. difficile Infection

April 23, 2018 Microbiome Times

Synthetic Biologics, Inc. (NYSE American: SYN), a late-stage clinical company developing therapeutics designed to preserve the microbiome to protect and restore the health of patients, today announced that it has preliminary agreement from the U.S. […]

Pharma & Human Health

AOBiome Therapeutics Expands Clinical-Stage Pipeline, Initiates Phase 2 Clinical Trial for Episodic Migraine

April 23, 2018 Microbiome Times

AOBiome Therapeutics (“AOBiome”), a clinical-stage life sciences company advancing patented microbiome-based therapies, today announced that AOBiome has expanded its clinical-stage pipeline with the initiation of a randomized, double-blind, Phase 2 study to assess safety, tolerability, […]

Pharma & Human Health

Prota Therapeutics Partners With World Leading Bioscience Company, Chr. Hansen

April 20, 2018 Microbiome Times

Allergy immunotherapy company Prota Therapeutics Pty Ltd (Prota), is pleased to announce it has partnered with Chr. Hansen, a leading global bioscience company, to manufacture and supply pharmaceutical quality LGG®1 probiotic strain, Lactobacillus rhamnosus, initially […]

Finance

MIT Spinout, ReviveMed, Raises $1.5M to Advance its AI-Driven Metabolomic Platform for Drug Discovery

April 20, 2018 Microbiome Times

ReviveMed Inc., today announced it has closed an oversubscribed seed round of $1.5 million to advance its artificial intelligence (AI)-driven platform that unlocks the value of metabolomics data for drug discovery and development. Rivas Capital […]

Finance

Inocucor $15.9M Final Close of Series B Financing Brings Series B Total to $54.4M

April 19, 2018 Microbiome Times

Inocucor Corporation, a developer and producer of biological crop inputs for high-value produce and row crops, announced the final close of its Series B funding round at $15.9 million with participation by existing investors Cycle […]

Posts navigation

1 2 »

Sign Up to Free Newsletter

The Microbiome Drug Database

Editor’s Choice

  • DynaMAP – Precision Metagenomics beyond Sequencing
    May 27, 2025
  • The Selection of a Pre-Clinical Model is Driven by the Specific Research Question
    May 13, 2025
  • Mental Health and the Brain-Gut-Microbiota Axis: Fundamental Importance of Diet
    April 3, 2025
  • Novel In vitro Model Replicates Intestinal Microbiota Composition Without Requiring Anaerobic Incubation
    March 25, 2025
  • Dynamic Microbiome Abundance Profiling: A new tool to solve challenges in microbiome analysis
    March 5, 2025
sign up

Sign up to the Microbiome Times newsletter